Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines
Purpose. To determine the clinical efficacy of recombinant human epidermal growth factor (rh-EGF) combined with povidone-iodine (PVI) on patients with pressure ulcers (PUs). Methods. One hundred and five PU patients treated between January 2018 and January 2021 were enrolled and retrospectively anal...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2022/3878320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553005794197504 |
|---|---|
| author | Zunjiang Zhao Dalun Lv Baode Zhang Liu Yong Rongtao Zhang Xiukun Wang |
| author_facet | Zunjiang Zhao Dalun Lv Baode Zhang Liu Yong Rongtao Zhang Xiukun Wang |
| author_sort | Zunjiang Zhao |
| collection | DOAJ |
| description | Purpose. To determine the clinical efficacy of recombinant human epidermal growth factor (rh-EGF) combined with povidone-iodine (PVI) on patients with pressure ulcers (PUs). Methods. One hundred and five PU patients treated between January 2018 and January 2021 were enrolled and retrospectively analyzed. Of them, 50 patients who received conventional treatment were assigned to the control group (Con group), while 55 patients treated with rh-EGF combined with PVI were assigned to the observation group (Obs group). The two groups were compared in clinical efficacy, PU alleviation (total area reduction rate, total depth reduction rate, and total volume reduction rate), healing time, pain degree (Visual Analog Scale [VAS] score), inflammatory indexes (interleukin-8 [IL-8], tumor necrosis factor-α [TNF-α], and hypersensitive C reactive protein [hs-CRP]), and hydroxyproline content in the wound. Results. The Obs group yielded a higher total effective rate than the Con group (P<0.05). The Obs group also experienced statistically shorter healing time and milder pain, with better PU alleviation and lower levels of inflammation indexes compared with the Con group (all P<0.05). In addition, a higher hydroxyproline content in the wound was found in the Obs group. Conclusions. All in all, rh-EGF combined with PVI has a definite curative effect on patients with PUs. It can promote PU alleviation and hydroxyproline secretion in the wound and inhibit pain and inflammatory reactions, which is worthy of clinical promotion. |
| format | Article |
| id | doaj-art-b609ce2df0cc4afb97910a955665778c |
| institution | Kabale University |
| issn | 1466-1861 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-b609ce2df0cc4afb97910a955665778c2025-02-03T05:57:22ZengWileyMediators of Inflammation1466-18612022-01-01202210.1155/2022/3878320Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory CytokinesZunjiang Zhao0Dalun Lv1Baode Zhang2Liu Yong3Rongtao Zhang4Xiukun Wang5Department of Burns and Plastic SurgeryDepartment of Burns and Plastic SurgeryDepartment of Burns and Plastic SurgeryDepartment of Burns and Plastic SurgeryDepartment of Burns and Plastic SurgeryDepartment of Burns and Plastic SurgeryPurpose. To determine the clinical efficacy of recombinant human epidermal growth factor (rh-EGF) combined with povidone-iodine (PVI) on patients with pressure ulcers (PUs). Methods. One hundred and five PU patients treated between January 2018 and January 2021 were enrolled and retrospectively analyzed. Of them, 50 patients who received conventional treatment were assigned to the control group (Con group), while 55 patients treated with rh-EGF combined with PVI were assigned to the observation group (Obs group). The two groups were compared in clinical efficacy, PU alleviation (total area reduction rate, total depth reduction rate, and total volume reduction rate), healing time, pain degree (Visual Analog Scale [VAS] score), inflammatory indexes (interleukin-8 [IL-8], tumor necrosis factor-α [TNF-α], and hypersensitive C reactive protein [hs-CRP]), and hydroxyproline content in the wound. Results. The Obs group yielded a higher total effective rate than the Con group (P<0.05). The Obs group also experienced statistically shorter healing time and milder pain, with better PU alleviation and lower levels of inflammation indexes compared with the Con group (all P<0.05). In addition, a higher hydroxyproline content in the wound was found in the Obs group. Conclusions. All in all, rh-EGF combined with PVI has a definite curative effect on patients with PUs. It can promote PU alleviation and hydroxyproline secretion in the wound and inhibit pain and inflammatory reactions, which is worthy of clinical promotion.http://dx.doi.org/10.1155/2022/3878320 |
| spellingShingle | Zunjiang Zhao Dalun Lv Baode Zhang Liu Yong Rongtao Zhang Xiukun Wang Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines Mediators of Inflammation |
| title | Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines |
| title_full | Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines |
| title_fullStr | Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines |
| title_full_unstemmed | Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines |
| title_short | Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines |
| title_sort | efficacy of human recombinant epidermal growth factor combined with povidone iodine for pressure ulcers and its influence on inflammatory cytokines |
| url | http://dx.doi.org/10.1155/2022/3878320 |
| work_keys_str_mv | AT zunjiangzhao efficacyofhumanrecombinantepidermalgrowthfactorcombinedwithpovidoneiodineforpressureulcersanditsinfluenceoninflammatorycytokines AT dalunlv efficacyofhumanrecombinantepidermalgrowthfactorcombinedwithpovidoneiodineforpressureulcersanditsinfluenceoninflammatorycytokines AT baodezhang efficacyofhumanrecombinantepidermalgrowthfactorcombinedwithpovidoneiodineforpressureulcersanditsinfluenceoninflammatorycytokines AT liuyong efficacyofhumanrecombinantepidermalgrowthfactorcombinedwithpovidoneiodineforpressureulcersanditsinfluenceoninflammatorycytokines AT rongtaozhang efficacyofhumanrecombinantepidermalgrowthfactorcombinedwithpovidoneiodineforpressureulcersanditsinfluenceoninflammatorycytokines AT xiukunwang efficacyofhumanrecombinantepidermalgrowthfactorcombinedwithpovidoneiodineforpressureulcersanditsinfluenceoninflammatorycytokines |